2014's Better Buy: Johnson & Johnson vs. Abbott Laboratories

Few stocks in health care are as recognizable as power players Johnson & Johnson (NYSE: JNJ  ) and Abbott Labs (NYSE: ABT  ) . Both diversified health-care firms have broad reaches across several industries in the health sector, and both have been reliable stocks for investors for decades. But which stock is on track to perform the best for your portfolio in 2014?

Johnson & Johnson's fresh off of its fourth-quarter earnings report, in which the company's standout pharmaceutical division continued to see sales surge. However, J&J's outlook instilled worry among some industry analysts, sending the stock down despite an earnings beat. Meanwhile, while Abbott saw its big growth driver, its nutritionals division, sag in its own earnings report, the company still has a big presence overseas in emerging markets it hopes to capitalize on this year.

Does that make Abbott the stock you should believe in, or is Johnson & Johnson's surging drug unit too tempting to pass up? Find out in the video below, where Motley Fool contributor Dan Carroll compares these two stocks in the wake of their earnings announcements and shows you which is on the better track to reward your financial foundation this year.

Is your financial future looking safe?
Abbott and Johnson & Johnson have rewarded investors handsomely over the years as safe, strong stocks, but millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2807828, ~/Articles/ArticleHandler.aspx, 8/1/2014 12:47:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement